Podcasts about therapies

Fear-based learning can intensify pain in people with IBD even when inflammation is no longer active, showing that emotional processing plays a major role in chronic symptoms IBD patients in remission reported significantly higher pain intensity and unpleasantness compared to healthy individuals, despite experiencing the exact same heat stimulus The brain can hold onto pain memories through a process called fear conditioning, which teaches the nervous system to expect discomfort even without a current physical trigger People with IBD often feel isolated and emotionally overwhelmed due to unpredictable flare-ups, brain fog, shame, and the invisible nature of their pain Therapies like cognitive behavioral therapy offer a promising path to reduce pain by addressing the brain's learned fear responses

Dr. Tesha Monteith talks with Dr. Michael Eller about the implications of CGRP therapies in migraine treatment, particularly for patients with vascular risk factors or a history of stroke.  Read the related article in Neurology®. Disclosures can be found at Neurology.org. 

As part of our official DealFlow Discovery Conference Interview Series, produced by Mission Matters, along with our partner DealFlow Events, we're showcasing the innovative companies presenting at the upcoming DealFlow Discovery Conference (January 28-29, at the Borgata in Atlantic City) and the executives behind them. In this episode, Adam Torres interviews Anil Diwan, Founder of NanoViricides Inc., about the company's mission to develop revolutionary antiviral therapies. Anil explains the vision for empiric antiviral treatment, the challenges of viral mutation, and how NanoViricides is advancing its approach through the NV-387 program. This interview is part of our effort to help investors discover compelling companies ahead of the event — and to help CEOs introduce their story to the 1500+ conference attendees. Learn more about the event and presenting companies:https://dealflowdiscoveryconference.com/ About Anil Diwan Dr. Diwan has been President and Chairman of the Board of the Company since its founding in 2005 Dr. Diwan spearheaded the efforts for the Company's 2013 uplisting from the OTC Markets to NYSE-American. Dr. Diwan has led several of the Company's financing efforts since 2010. About NanoViricides Inc. NanoViricides, Inc. is a global leader in the development of nanomedicine drugs against viruses. Our unique nanoviricide® platform technology defines a novel mechanism enabling first-in class drugs against viruses. A nanoviricide is designed to specifically attack enveloped virus particles, on the same sites that they use to bind to cells, and dismantle them, blocking reinfection cycle, going beyond what antibodies and immunotherapeutics do. A nanoviricide can also be designed to deliver anti-viral payload into infected cells sparing uninfected cells to block replication cycle without toxicity. Our unique biomimetic approach enables creation of drugs that a virus would be highly unlikely to escape due to mutations. Follow Adam on Instagram at https://www.instagram.com/askadamtorres/ for up to date information on book releases and tour schedule. Apply to be a guest on our podcast: https://missionmatters.lpages.co/podcastguest/ Visit our website: https://missionmatters.com/ More FREE content from Mission Matters here: https://linktr.ee/missionmattersmedia Learn more about your ad choices. Visit podcastchoices.com/adchoices

Send us a textWelcome back to the Coven of Awesomeness Podcast! First off, let us apologies for the audio quality in this episode. We had a technical hiccup which stopped us from being able to remove as much of the background noise as we usually would, so we are aware that it's not our usual quality and we apologise!But to make it up to you, this episode features the incredible Kelly from Saturn Therapies who has come along to talk to us about past lives. But first, what are we eating?? Louise has been visiting IKEA under the guise of furniture shopping, but really just  to eat the famous meatballs. Renee has been creating a delicious chocolate peanut butter cheesecake, and Kelly has been working her way through the Christmas chocolates.Then we get into the good stuff. Kelly talks us through her journey with past lives work and  shared some amazing insights into how tapping into your past lives can be transformative in your current life.And then we finish, as always, with awesomeness. Renee has been getting to do the good stuff in her business, Louise is ticking those 2026 goals off the list, and Kelly is planning a much-anticipated past lives retreat.Support the showIf you're able, give this podcast your support by joining the International Coven of Awesomeness on Patreon so we can keep sharing witchy content for that's free for all.Get your free ebook How to Work with the Moon to Get Things Done.Check out the latest workshop offerings from the STC Witchcraft Academy for both online workshops and in-person circles in the Glasgow, Scotland area.Find all your favorite recipes and witch tips at Awesome on 20 Kitchen Magick.Book a tarot reading with Renee at Sagittarian Tarot & Coaching. Join the Moon Magic Membership coven to receiving ongoing support in your witchcraft journey. Join our Coven of Awesomeness Facebook group open to everyone.

From Discovery to Delivery: Charting Progress in Gynecologic Oncology, hosted by Ursula A. Matulonis, MD, brings expert insights into the most recent breakthroughs, evolving standards, and emerging therapies across gynecologic cancers. Dr Matulonis is chief of the Division of Gynecologic Oncology and the Brock-Wilcon Family Chair at the Dana-Farber Cancer Institute, as well as a professor of medicine at Harvard Medical School, both in Boston, Massachusetts.In this episode, Dr Matulonis sat down with guest Rebecca Porter, MD, PhD. Dr Porter is a physician at Dana-Farber Cancer Institute and an assistant professor of medicine at Harvard Medical School.Drs Matulonis and Porter discussed the evolving role of immunotherapy in gynecologic cancer management, focusing on recent clinical breakthroughs and future directions. They noted that although high-grade serous ovarian cancer has historically been refractory to immunotherapy, the phase 3 KEYNOTE-B96 trial (NCT05116189) demonstrated an efficacy benefit with the addition of pembrolizumab to weekly paclitaxel for patients with platinum-resistant disease. In particular, improvements in overall survival were noted in the PD-L1–positive patient population. Dr Porter attributed this success to the metronomic weekly dosing of paclitaxel, which may increase neoantigen levels and favorably alter the tumor microenvironment (TME).Moreover, the experts highlighted how immunotherapy has already become the standard of care for patients with mismatch repair–deficient advanced or recurrent endometrial cancer. However, they explained that for the mismatch repair–proficient population, this benefit is less clear and appears most significant in patients with measurable disease or specific molecular subtypes. They added that although circulating tumor DNA (ctDNA) assay results correlate with treatment outcomes, ctDNA is currently not an actionable biomarker for determining treatment duration or selection.Lastly, Drs Matulonis and Porter reported that the field of gynecologic oncology is shifting toward combination therapies and novel platforms beyond standard checkpoint inhibitors. Treatment advances include bispecific and trispecific antibodies that engage multiple cell types or signals; as well as adoptive cellular therapies, such as CAR T-cell and CAR natural killer–cell therapies. Ultimately, the experts concluded that the goal of managing challenging-to-treat diseases like ovarian cancer is to use combinatorial approaches—incorporating vaccines, anti-angiogenic therapies, and chemotherapy—to overcome the immunosuppressive nature of the TME.

This Biotech CEO Is Creating Advanced & Personalized Therapies To Fight Cancer.Full Name: Thomas JensenTitle: Chief Executive Officer, Allarity Therapeutics Ticker: $ALLRWebsite: https://www.allarity.com/Bio:Thomas Jensen is the Chief Executive Officer of Allarity Therapeutics (NASDAQ: ALLR), a clinical-stage biopharmaceutical company advancing personalized cancer therapies. He was appointed CEO in December 2023 after nearly a decade as Chief Technology Officer, during which he helped pioneer the company's proprietary Drug Response Predictor (DRP®) platform.With over 20 years in the biotech and precision medicine space, Thomas has led Allarity through a focused strategic transformation centered on stenoparib—a first-in-class dual PARP/tankyrase inhibitor currently in Phase 2 trials for advanced ovarian cancer. Under his leadership, Allarity has achieved FDA Fast Track designation, formed key research collaborations, and presented clinical data showing landmark median overall survival of ovarian cancer patients.Company Bio:Allarity Therapeutics (NASDAQ: ALLR) is a clinical-stage biopharma company developing personalized cancer treatments guided by its proprietary DRP® companion diagnostic platform. The company's lead asset, stenoparib, is a novel, orally available dual PARP and WNT pathway inhibitor being evaluated in Phase 2 trials for advanced ovarian cancer. With headquarters in the U.S. and a research facility in Denmark, Allarity is committed to improving patient outcomes through precision oncology. Learn more at www.allarity.com

View the Show Notes Page for This Episode Become a Member to Receive Exclusive Content Sign Up to Receive Peter's Weekly Newsletter Lisa Mosconi is a world-renowned neuroscientist and the director of the Women's Brain Initiative at Weill Cornell Medicine, where she studies how sex differences and hormonal transitions influence brain aging and Alzheimer's disease risk. In this episode, Lisa explores why Alzheimer's disease disproportionately affects women and why longer lifespan alone does not explain their nearly twofold risk compared to men. She explains why Alzheimer's disease may be best understood as a midlife disease for women, beginning decades before symptoms appear, and how menopause represents a fundamental brain event that reshapes brain energy use, structure, and immune signaling. The conversation also examines what advanced brain imaging reveals about preclinical Alzheimer's disease, estrogen receptors in the brain, and why genetic risks such as APOE4 appear to affect women differently from men. Finally, Lisa discusses the nuanced evidence around menopause hormone therapy, the legacy of the WHI, her new CARE Initiative to cut women's Alzheimer's risk in half by 2050, and practical, evidence-based strategies to support brain health through midlife—including lifestyle, sleep, metabolism, mood, and emerging therapies such as GLP-1 agonists and SERMs (selective estrogen receptor modulators). We discuss: How Lisa's personal family history and scientific background led her to focus on the intersection of women's health, brain aging, and Alzheimer's disease (AD) [2:45]; The long preclinical phase of AD and the emotional burden carried by patients before dementia becomes severe [7:15]; How AD compares to other common forms of dementia: prevalence, pathology, symptoms, diagnostic challenges, and more [10:45]; Why AD disproportionately affects women: how AD is not simply a disease of old age or longevity but a midlife disease in which women develop pathology earlier [16:15]; Menopause as a leading explanation for women's increased Alzheimer's risk, and how advanced braining imaging can detect early changes in the brain [26:15]; How a new method for imaging estrogen receptors in the brain is changing how we think about the menopause transition [35:45]; What estrogen receptor imaging can and cannot tell us about hormone therapy's potential impact on brain health [48:45]; Lisa's studies on the relationship between levels of systemic estrogen and density of estrogen receptors in the brain [58:00]; Why blood estrogen levels poorly reflect brain estrogen signaling, and how tightly regulated brain hormone dynamics complicate our understanding of menstrual-cycle and lifestyle effects [1:02:15]; The CARE Initiative: Lisa's research program looking to slash AD rates in women [1:07:45]; The dramatic difference in AD risk between men and women associated with APOE4 [1:10:45]; What the evidence suggests about menopausal hormone therapy (MHT) and AD risk, and why timing, formulation, and uterine status appear to matter [1:12:00]; How the CARE initiative plans to study MHT and AD risk, within the practical constraints of a three-year research window [1:17:30]; How to think about starting hormone therapy during perimenopause: balancing symptom relief, hormonal variability, and individualized care [1:21:00]; Investigating selective estrogen receptor modulators (SERMs) as a targeted approach to brain health during and after menopause [1:25:00]; Why estrogen became wrongly associated with cancer risk and what the evidence actually shows [1:29:30]; Why better biomarkers are central to advancing women's Alzheimer's research [1:38:30]; Modifiable risk factors for dementia, the limitations of risk models, and questionable conclusions drawn from observational data [1:44:15]; GLP-1 agonists and brain health: exploring potential neuroprotective effects of GLP-1 agonists beyond metabolic benefits [1:49:00]; The importance of lifestyle factors in reducing risk of dementia: practical strategies for women to support brain health [1:53:45]; Why long-term, consistent lifestyle habits are essential for building cognitive resilience and protecting brain health over decades [2:01:15]; and More. Connect With Peter on Twitter, Instagram, Facebook and YouTube

To watch the video of this podcast, please go to: https://youtu.be/q26VN0EWhbg   How can we reclaim our connection to the Earth to find deep, somatic healing? What if nature therapy is actually a return to our most essential human blueprint? What if the thresholds of our lives—those messy, in-between spaces—are actually sacred ceremonies waiting to be honored?   In this episode of Kaleidoscope of Possibilities, Dr. Adriana Popescu is joined by Katie Asmus, a somatic and nature-based psychotherapist with over 30 years of experience leading individuals back to themselves through the natural world. Together, they explore the intersection of somatic psychology, wilderness therapy, and the ancient art of ceremony. This conversation invites you to step out of the digital noise and back into the grounded wisdom of your own body and the greater web of life.   In this episode: The Power of Somatic Nature Therapy: Discover how combining body-based awareness with the natural world creates a unique "co-therapy" relationship with the Earth. The Science of Connection: Explore how nature acts as a natural regulator for the nervous system, offering a safe container for trauma processing. Healing the "Source of Trauma:” Why nature and animals often feel safer than humans for those recovering from interpersonal trauma. Normalizing the Human Experience: Bringing compassion to the "human-ness" of our struggles through the lens of nature's cycles.   Resources mentioned in this episode: Katie's website: Somatic Nature Therapy Institute: https://www.somaticnaturetherapy.com/ Free Resources: Ceremony Creation Guide and Nature Meditations: https://www.somaticnaturetherapy.com/downloadable-resources   About Katie: Katie Asmus is a Somatic and Nature-Based Psychotherapist. With a Master's degree in Somatic Psychology, over 30 years of leading individuals and group programs out in nature, and a lifetime of apprenticing to ceremony and rites of passage, Katie says the essence of her work is normalizing, celebrating, and bringing compassion to what it means to be human. For the past 20 years, alongside maintaining a private psychotherapy practice, she has taught graduate students at Naropa University and Prescott College in the areas of Somatic and Nature-based Therapies. In addition, through the Somatic Nature Therapy Institute (and in collaboration with other inspiring colleagues), she created and facilitates both online and in-person workshops and trainings in Somatic Trauma work, Ceremony & Rites of Passage facilitation, as well as in a wide variety of wilderness, adventure, and nature-based therapy skills. Having sat with thousands of people from around the world and from all walks of life, Katie is a tender of the thresholds and strongly believes in the necessity of following our deepest longing while simultaneously knowing and feeling our interconnection and belonging to the greater web of life.   “The essence of my work is normalizing, celebrating, and bringing compassion to what it means to be human.” – Katie   Would you like to continue this conversation and connect with other people who are interested in exploring these topics? Please join us on our Facebook group! (https://www.facebook.com/groups/kaleidoscopeofpossibilitiespodcast/)   About your host: Dr. Adriana Popescu is a clinical psychologist, addiction and trauma specialist, author, speaker and empowerment coach who is based in San Francisco, California and practices worldwide. She is the author of the book, What If You're Not As F***ed Up As You Think You Are? For more information on Dr. Adriana, her sessions and classes, please visit: https://adrianapopescu.org/ To find the book please visit: https://whatifyourenot.com/ To learn about her trauma treatment center Firebird Healing, please visit the website: https://www.firebird-healing.com/   You can also follow her on social media:  Facebook: https://www.facebook.com/DrAdrianaPopescu/ Instagram: https://www.instagram.com/dradrianapopescu/?hl=en LinkedIn: https://www.linkedin.com/in/adriana-popescu-ph-d-03793 Youtube: https://www.youtube.com/channel/UCflL0zScRAZI3mEnzb6viVA TikTok: https://www.tiktok.com/@dradrianapopescu? Medium: https://medium.com/@dradrianapopescu   Disclaimer: This podcast represents the opinions of Dr. Adriana Popescu and her guests. The content expressed therein should not be taken as psychological or medical advice. The content here is for informational or entertainment purposes only. Please consult your healthcare professional for any medical or treatment questions. This website or podcast is not to be used in any legal capacity whatsoever, including but not limited to establishing “standard of care” in any legal sense or as a basis for legal proceedings or expert witness testimony. Listening, reading, emailing, or interacting on social media with our content in no way establishes a client-therapist relationship.  

In this podcast, experts William J. Gradishar, MD, FASCO, FACP; Stephanie L. Graff, MD, FACP, FASCO; and Cynthia X. Ma, MD, PhD; discuss current and emerging therapeutic options, including next-generation endocrine therapies, to target the estrogen receptor signaling pathway for the treatment of hormone receptor–positive/HER2-negative (HR+/HER2–) metastatic breast cancer (MBC).

Send us a textCould a simple blood test help identify chronic pulmonary hypertension when echo access is limited? This week on The Incubator Podcast, Ben and Daphna explore this question and others relevant to daily NICU practice. A Toronto study examines NT-proBNP as a practical diagnostic tool in extremely preterm infants.They also examine a puzzling finding from Italy and Belgium: despite near-universal antibiotic use in neonates with HIE undergoing cooling, actual culture-positive sepsis rates are surprisingly low. What does this mean for our approach to empiric antibiotics?Ben presents Norwegian data showing that serial physical exams cut antibiotic exposure in half for term and late preterm infants—without compromising safety. Daphna follows with research connecting NICU capacity strain to patient outcomes, underscoring why adequate staffing isn't just about comfort, but about survival.The episode concludes with Ben, Daphna, and Eli discussing the recent CDC changes to Hepatitis B birth dose recommendations. With federal guidance now diverging from AAP recommendations, how do we navigate conversations with families? They explore transmission risks parents may overlook and share approaches to shared decision-making when expert opinions conflict. A full week of neonatal medicine research and real-world clinical challenges, all in one episodeSupport the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!

Send us a textThis week on Neo News, we tackle the recent and controversial divergence between CDC and AAP guidelines regarding the birth dose of the Hepatitis B vaccine. With the CDC now recommending a deferred schedule for infants of Hepatitis B-negative mothers, we explore the clinical implications, the risks of vertical transmission, and the challenge of navigating discordant public health advice. We discuss how to handle shared decision-making in an era of waning vaccine confidence and why the "birth dose" remains a critical safety net in a community setting. Join us as we break down the data behind the headlines.----American Academy of Pediatrics. (2025, December 15). AAP: CDC decision on universal birth dose of hepatitis B vaccine irresponsible and purposely misleading. AAP News. https://publications.aap.org/aapnews/news/33980/AAP-CDC-decision-on-universal-birth-dose-of?searchresult=1?autologincheck=redirectedSupport the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!

Send us a textIn this episode of Journal Club, Ben and Daphna review a retrospective cohort study from the Journal of Perinatology examining the association between NICU capacity strain and neonatal outcomes. We discuss how high census and acuity on admission day correlate with increased mortality and morbidity when adjusted for hospital and patient factors. Join us as we explore why being "slammed with admissions" is more than just a badge of honor—it's a critical safety metric for our patients.----The association of NICU capacity strain with neonatal mortality and morbidity. Salazar EG, Passarella M, Formanowski B, Rogowski J, Edwards EM, Halpern SD, Phibbs C, Lorch SA.J Perinatol. 2025 Dec;45(12):1801-1808. doi: 10.1038/s41372-025-02449-0. Epub 2025 Oct 20.PMID: 41116036 Free PMC article.Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!

We love to hear from our listeners. Send us a message.Welcome to episode 120 of Cell & Gene: The Podcast. Host Erin Harris is joined by Rachel Haurwitz, CEO of Caribou Biosciences, to discuss the company's progress in developing CRISPR-edited, off-the-shelf CAR-T therapies for hematologic malignancies. Their conversation centers on Vispacell, Caribou's allogeneic CD19 CAR-T for second-line large B-cell lymphoma. Haurwitz explains how Caribou has systematically optimized its allogeneic platform using clinical and translational data. They also cover pivotal Phase 3 trial planning, regulatory considerations, and what to expect next from Caribou's broader pipeline, including its BCMA-targeted program in multiple myeloma.Subscribe to the podcast!Apple | Spotify | YouTube Visit my website: Cell & Gene Connect with me on LinkedIn

Oncologist George Georges, MD, moderates a discussion with Christine Hsieh, MD, rheumatologist, and Arjun Seth, MD, neurologist, on advancing care for inflammatory myopathies. The panel introduces the Northwestern Medicine Myositis Clinic, a one-stop model that simplifies diagnostics and connects patients to clinical trials. They review current treatment strategies — steroids, IVIg, steroid-sparing agents, rituximab, and JAK inhibitors — along with approaches for refractory disease. The panel also explores cellular therapies, including CAR-T cell trials.

Send us a textIn this episode of The Incubator Podcast, Ben and Daphna review a pivotal population-based study from Norway examining a new approach to Early-Onset Sepsis (EOS). The hosts discuss whether serial physical examinations can safely replace routine antibiotic prophylaxis in at-risk term and late-preterm infants. With antibiotic exposure often far exceeding sepsis incidence, this study offers compelling data for a "less is more" strategy. Tune in as Ben and Daphna explore the safety, efficacy, and bedside implications of substituting automatic treatment with structured clinical monitoring—and what this means for reducing unnecessary interventions in the NICU.----Serial physical examination to reduce unnecessary antibiotic exposure in newborn infants: a population-based study. Vatne A, Eriksen BHH, Bergqvist F, Fagerli I, Guthe HJT, Iversen KV, Ud Din FS, van der Weijde J, Kvaløy JT, Rettedal S.Arch Dis Child Fetal Neonatal Ed. 2025 Nov 19:fetalneonatal-2025-329639. doi: 10.1136/archdischild-2025-329639. Online ahead of print.PMID: 41260908Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete EBAC/CME information, and to apply for credit, please visit us at PeerView.com/WBF865. EBAC/CME credit will be available until December 30, 2026.New Kids on the Block in mHSPC: Personalising Approaches Through Emerging Precision Therapies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/NXT865. CME/MOC/NCPD/AAPA/IPCE credit will be available until January 15, 2027.Dialing Up Precision in HR+, HER2- MBC With New Endocrine Agents, Targeted Therapies, and Combinations: A Framework for Multifactorial Clinical Decisions In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Living Beyond Breast Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, Genentech, a member of the Roche Group, Lilly, and Stemline Therapeutics, a Menarini Company Group.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/ARY865. CME/MOC/AAPA/IPCE credit will be available until January 18, 2027.Elevating NMIBC Care: Putting the Latest Innovations for Intravesical Therapies Into Practice In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Johnson & Johnson.Disclosure information is available at the beginning of the video presentation.

Send us a textIn this Journal Club episode of the Incubator Podcast, Ben Courchia and Daphna Yasova-Barbeau review a study from the Journal of Perinatology evaluating NT-proBNP as a diagnostic tool for chronic pulmonary hypertension in extremely preterm infants. The discussion walks through the clinical burden of pulmonary hypertension in babies with bronchopulmonary dysplasia, the limitations of echocardiography, and the appeal of accessible biomarkers. Using data from a SickKids Toronto cohort, the hosts unpack sensitivity, specificity, cutoff values, and real-world applicability, while exploring how NT-proBNP could support screening, risk stratification, and bedside decision-making in everyday NICU practice.----Can N-terminal pro-brain natriuretic peptide accurately diagnose chronic pulmonary hypertension among extremely low gestational age neonates: A Retrospective Cohort Study. Garcia-Gozalo M, Jain A, Weisz DE, Jasani B.J Perinatol. 2025 Nov 13. doi: 10.1038/s41372-025-02462-3. Online ahead of print.PMID: 41233504Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!

How is advanced genetic engineering, stem cell biology, and AI-driven analytics reshaping the future of brain repair? Dr. Ruslan Rust, an Assistant Professor of Research Physiology and Neuroscience at the Keck School of Medicine of USC, joins the podcast to share his insights… With over 15 years of translational neuroscience research, Dr. Rust is developing next-generation gene-edited, induced pluripotent stem cell (iPSC)-derived therapies designed to overcome the biggest barriers in cell therapy — crossing the blood-brain barrier, immune rejection, and long-term safety. Dive in now to find out: Why current stem cell therapies struggle in stroke and neurodegenerative disease. Where stem cells are harvested.  How gene-edited iPSC-derived cells are engineered to cross the blood-brain barrier. The role of AI and single-cell omics in optimizing brain repair strategies. With additional training in MBA, bio-entrepreneurship, and scientific leadership, Dr. Rust brings a uniquely pragmatic lens to what it actually takes to turn cutting-edge neuroscience into viable therapies. Listen now for a rare look at how stroke recovery and Alzheimer's treatment may move from experimental promise to real clinical impact. You can keep up with Ruslan on X or by visiting his USC academic website!

Send us a textIn this Journal Club episode, Ben and Daphna review a large national cohort study examining the association between antenatal corticosteroid exposure and survival in extremely preterm infants born between 21 and 24 weeks' gestation. They discuss biologic plausibility, practice variation, and the challenges of interpreting retrospective data, while focusing on how these findings may inform counseling and shared decision-making at the margins of viability.----The Effects of Antenatal Corticosteroids on Extremely Premature Neonates Born between 21 and 24 Weeks. Yao R, Tritch N, Vedhanayagam K, Ali N, Reimche-Vu H, Gedestad I, Karageuzian S, Contag S.Am J Perinatol. 2025 Nov 6. doi: 10.1055/a-2722-8107. Online ahead of print. PMID: 41086871Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!

Wanna jump in the ice bath?See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Send us a textBen and Daphna review the ICAF randomized clinical trial evaluating extended caffeine therapy in preterm infants and its impact on intermittent hypoxia through 41 weeks postmenstrual age. They discuss the study design, oximetry outcomes across multiple saturation thresholds, inflammatory biomarkers including TNF-α, and clinically relevant safety signals such as oxygen restart rates, length of stay, and weight gain. The conversation focuses on what intermittent hypoxia may mean for ongoing risk, and whether a targeted subgroup of infants might benefit from extending caffeine beyond traditional stopping points.----Intermittent hypoxia and caffeine in infants born preterm: the ICAF Randomized Clinical Trial. Eichenwald E, Corwin M, McEntire B, Knoblach S, Limperopoulos C, Kapse K, Kerr S, Heeren TC, Ikponmwonba C, Hunt CE; ICAF Study Group.Arch Dis Child Fetal Neonatal Ed. 2025 Nov 24:fetalneonatal-2025-329230. doi: 10.1136/archdischild-2025-329230. Online ahead of print.PMID: 41285561Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!

On this week's episode of Love University, we're joined by Anne Abel, acclaimed memoirist, storyteller, and TikTok inspiration, whose book High Hopes (https://tinyurl.com/3bhmfb9t) recounts one woman's unexpected reinvention. After decades of treatment-resistant depression—including psychiatric hospitalization and electroconvulsive therapy (ECT)—Anne made a single, life-changing decision: she said “yes” to a solo 26-day trip to Australia to follow Bruce Springsteen on tour. That journey, at age 60, became far more than an adventure. It was the beginning of a full emotional reawakening. Here are three powerful insights from her story: The Cure to Sadness May Be as Simple as One “Yes” For much of her adult life, Anne lived behind a wall of emotional numbness. Highly educated, married, and outwardly functional, she moved through the world with deep internal pain. Therapies had come and gone. ECT helped, briefly. But nothing truly shifted—until she gave herself permission to act on something instinctual. That “yes” to a Springsteen concert tour—unreasonable, unplanned—became a way back to her authentic, powerful self. Healing Begins When You Stop Waiting to Feel Ready Anne didn't fly to Australia because she felt courageous. She did it because she knew she couldn't stay in the life she was living. Surrounded by strangers in packed Springsteen arenas, she found something she hadn't felt in years: vitality, meaning, and self-validation. The music, the lyrics, the crowd energy—they stirred emotions that had long been locked away. Bruce didn't just perform—he mirrored her back to herself. She began to feel, to connect, to hope. That alone was its own kind of healing. You Are Not Defined by Your Past—Unless You Keep Replaying It High Hopes is more than a travel memoir. It's a guide to emotional renewal, bold reinvention, and reclaiming your voice after years of silence. Anne shows that transformation doesn't require perfection—it needs permission. Through movement, music, and saying “yes” before she felt “ready,” she rewrote her narrative. Depression may have shaped her past, but it no longer had the final word. Her life began again when she stopped waiting for conditions to be perfect—and chose to live anyway. You can follow Anne's example by listening to your intuition and saying “Yes” to the calling of your soul.

Breath to Breath Film that celebrates the contributions by Dr. Michael WelshA Conversation with Dr. Michael Welsh: The Science That is Saving LivesIt's always such a privilege to feature CF icons on the podcast. Over the years, we've been fortunate to host some of the most influential names in cystic fibrosis research, including Dr. Francis Collins, the former director of the NIH and one of the authors of the Human Genome Project, and his longtime friend Dr. Mitch Drumm, who was working on his doctorate when the CF gene was discovered back in 1989.I actually saw Mitch recently at a dinner, and as many of you know, Dr. Collins continues to be a tireless advocate for good science and for sharing its importance with the world.And now, we add another legend to that list: Dr. Michael Welsh from the University of Iowa.Dr. Welsh tells his story beautifully in the University's film Breath by Breath: Living with Cystic Fibrosis. In it, he describes how his curiosity about the CFTR protein led to groundbreaking discoveries that ultimately laid the foundation for CF therapies, the very treatments that have changed (and saved) thousands of lives, including the lives of my daughters.Dr. Welsh's career is extraordinary, spanning decades of research, mentorship, and discovery. He's the Carver Professor of Internal Medicine and Molecular Physiology and Biophysics at the University of Iowa, and from 1989 to 2024, he served as an Investigator with the Howard Hughes Medical Institute. He currently directs both the Pappajohn Biomedical Institute and the Cystic Fibrosis Research Center.We've linked both his full bio and the film in the show notes, and I highly encourage you to check them out. His accolades could fill pages, actually, an entire book! We had so many laughs too in this podcast! So much fun. You'll really enjoy it.Dr. Welsh shared insights not only into his scientific journey, but also the heart behind the work. He recently received the Lasker Award for pioneering CF research that led to life-saving therapies, a recognition that celebrates decades of persistence, curiosity, and collaboration.We discussed so much:How his team began unraveling the mystery of the CFTR protein and what that breakthrough moment felt likeWhat it's like to see patients thriving because of the treatments that grew from that workWhy the University of Iowa decided to produce Breath by Breath, and what the film means to him personallyWhat new treatments and discoveries he's exploring nowHearing Dr. Welsh describe the intersection of science, hope, and humanity is powerful. You can tell that for him, this work isn't just research, it's a mission.As the documentary shows, CF isn't just a disease studied under a microscope. It's a lived experience for patients and families, one that now includes real hope thanks to the breakthroughs made by scientists like Dr. Michael Welsh.Biography:Dr. Michael Welsh is the Carver Professor of Internal Medicine and Molecular Physiology andBiophysics at the University of Iowa. From 1989-2024, he was an Investigator of the HowardHughes Medical Institute. He directs the Pappajohn Biomedical Institute and the Cystic FibrosisResearch Center.Dr. Welsh obtained an MD and completed an internal medicine residency at the University ofIowa. He then trained in pulmonary medicine and research at the University of California, SanFrancisco and physiology at the University of Texas, Houston.Dr. Welsh and his colleagues discovered that the protein affected in cystic fibrosis is an anionchannel, elucidated its functional mechanisms, discovered ways that mutations disrupt function,and showed that mutations can be rescued. This work led directly to development of medicinesthat target CFTR and are highly effective for most cystic fibrosis patients. To understand diseasepathogenesis, he and his collaborators developed cystic fibrosis pigs, the first mammal, otherthan mice, in which a gene was targeted to generate a disease model.His clinical activities focused on pulmonary diseases. He has trained many physicians andscientists and received the Distinguished Mentor Award, University of Iowa Carver College ofMedicine.To watch the film, click here:  https://uihealthcare.org/cystic-fibrosis-research-iowa#documentaryTo learn more about Dr. Welsh: https://internalmedicine.medicine.uiowa.edu/profile/michael-welsh Please like, subscribe, and comment on our podcasts!Please consider making a donation: https://thebonnellfoundation.org/donate/The Bonnell Foundation website:https://thebonnellfoundation.orgEmail us at: thebonnellfoundation@gmail.com Watch our podcasts on YouTube: https://www.youtube.com/@laurabonnell1136/featuredThanks to our sponsors:Vertex: https://www.vrtx.comViatris: https://www.viatris.com/en

In this episode, we get an update on Anti-Amyloid therapies and ARIA, along with the new POC tool to help physicians navigate these therapeutics and how they may impact patients in the emergency department. We talk with Dr. Christina Shenvi who introduced us to ARIA earlier in the year and now we have more evidence and a POC tool. Supported by Eli Lilly, USA

Experts decode American Society of Nephrology (ASN) 2025 immunoglobulin A (IgA) nephropathy trials: B‑cell therapies, who benefits, and practical steps to improve patient care. Credit available for this activity expires: 12/24/2026 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/navigating-advances-iga-nephropathy-key-developments-2025a100105j?ecd=bdc_podcast_libsyn_mscpedu

Shunji Tomatsu, MD, PhD, Professor and Head, Nemours Children's Health, Delaware, USA; Alessandra d'Azzo, PhD, Emerita Faculty, Genetics, St. Jude Children's Research Hospital, Tennessee, USA; Merve Emecen Sanli, MD, Associate Professor, Department of Pediatrics, University of Texas Southwestern Medical Center, Texas, USA; and Ryan Colburn, patient with Pompe disease and president of Odimm Inc, discuss new and emerging gene therapies for lysosomal disorders.This continuing education activity is provided through collaboration between the Lysosomal and Rare Disorders Research and Treatment Center (LDRTC), CheckRare CE, and AffinityCE. This activity provides continuing education credit for physicians, physician assistants, nurses, nurse practitioners, and genetic counselors. A statement of participation is available to other attendees.To obtain CME/CE credit, please visit https://checkrare.com/learning/p-grids2025-session6-current-issues-in-gene-therapies-for-lysosomal-disorders/  Learning ObjectivesDescribe current and emerging gene therapy data in lysosomal disorders and its clinical relevanceDescribe role of patients in gene therapy developmentFacultyShunji Tomatsu, MD, PhD, Professor and Head, Nemours Children's HealthAlessandra d'Azzo, PhD, Emerita Faculty, Genetics, St. Jude Children's Research HospitalMerve Emecen Sanli, MD, Associate Professor, Department of Pediatrics, University of Texas Southwestern Medical CenterRyan Colburn. Odimm, Inc.DisclosuresAffinityCE staff, LDRTC staff, planners, and reviewers, have no relevant financial relationships with ineligible companies to disclose. Faculty disclosures, listed below, will also be disclosed at the beginning of the Program.Shunji Tomatsu, MD, PhD Dr. Tomatsu has received the following grants: Morquio Foundations and families: Scarlett Grifith, Bennett, A Cure for Roberts, and Morquio Conference; MPS Societies: Japanese, National, and Austrian; NIH grants: 1-R01-HD102545, NIH, NICHD, Tomatsu (PI), 1R01HD104814-01A1, NIH, NICHD, Langan, T.J. (PI), Role: Site-PI, R43HD114328-01, NIH, ACOSTA, WALTER (PI), Role: site PI, 1R43AR084638-01, NIH, MOUNZIH, KHALID (PI); Foundation of NIH: FNIH RFP NUMBER: 2022-BGTC-005 Tomatsu (PI). Alessandra d'Azzo, PhDDr. D'Azzo has no relevant financial relationships to disclose.Merve Emecen Sanli, MDDr. Sanli has no relevant financial relationships to disclose.Ryan ColburnMr. Colburn has an advisory, consulting and/or project based relationship or stock holding with: Abeona Therapeutics, Amicus Therapeutics, Astellas Gene Therapies, Avidity Biosciences, Bayer, Catalyst Pharmaceuticals, Denali Therapeutics, M6P Therapeutics, Sangamo Therapeutics, Sanofi, Solid Biosciences.Mitigation of Relevant Financial RelationshipsAffinityCE adheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity. Conflicts of interest for presenting faculty with relevant financial interests were resolved through peer review of content by a non-conflicted reviewer.Accreditation and Credit DesignationPhysiciansThis activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and the LDRTC. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.AffinityCE designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.Physician AssistantsAffinityCE designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credits™. Physician Assistants should claim only the credit commensurate with the extent of their participation in the activity.NursesAffinityCE is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation (ANCC). This activity provides a maximum of 1 hours of continuing nursing education credit.Nurse PractitionersAffinityCE designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credits™. Nurse practitioners should claim only the credit commensurate with the extent of their participation in the activity.Genetic CounselorsAffinityCE designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credits™. Genetic Counselors should claim only the credit commensurate with the extent of their participation in the activity.Other ProfessionalsAll other health care professionals completing this continuing education activity will be issued a statement of participation indicating the number of hours of continuing education credit. This may be used for professional education CE credit. Please consult your accrediting organization or licensing board for their acceptance of this CE activity. Participation CostsThere is no cost to participate in this activity.CME InquiriesFor all CME policy-related inquiries, please contact us at ce@affinityced.comSend customer support requests to cds_support+ldrtc@affinityced.com

While endometriosis is highly associated with Chronic Pelvic Pian (CPP), some women may suffer from a different primary or coexistent secondary etiology: pelvic vascular congestion, called vascular origin (VO)- CPP. Although controversial as an entity, there have been diagnostic algorithms published (via pelvic ultrasound. MRI, or venography) for this condition. Approximately 10-40% of chronic pelvic pain cases may be attributed to pelvic vascular congestion (now termed pelvic venous disorder), though estimates vary considerably depending on the population studied and diagnostic criteria used. In premenopausal women specifically, the prevalence appears higher. One study found that 8% of all premenopausal women had documented chronic pelvic pain of unclear etiology along with dilated ovarian and pelvic veins on cross-sectional imaging. Therapies for this have been limited. Flavonoids are abundant in a colorful diet of fruits, vegetables, tea, and wine, with common sources including citrus fruits (flavanones), berries, apples, grapes (flavan-3-ols/anthocyanins), onions, kale, broccoli (flavonols), and tea, cocoa, red wine (flavan-3-ols), plus soybeans (isoflavones), all providing antioxidants and potential health benefits like better heart and brain health. On Dec. 23, 2025, in the journal Phlebology, researchers published a systematic review on the potential benefits of specific flavonoid mixtures which may provide relief to VO-CPP. Listen in for insights and details.1. Gloviczki ML, Demetres MR, Salazar G, Khilnani NM. Venoactive drugs for venous origin chronic pelvic pain in women: A systematic review. Phlebology. 2025 Dec 23:2683555251411027. doi: 10.1177/02683555251411027. Epub ahead of print. PMID: 41432346.2. Knuttinen MG, Machan L, Khilnani NM, Louie M, Caridi TM, Gupta R, Winokur RS. Diagnosis and Management of Pelvic Venous Disorders: AJR Expert Panel Narrative Review. AJR Am J Roentgenol. 2023 Nov;221(5):565-574. doi: 10.2214/AJR.22.28796. Epub 2023 Apr 5. PMID: 37095667.

Drs. Herzberg and Yu continue their discussion on emerging clinical data presented at ESMO and WCLC 2025. They highlight recent advancements in HER2-targeted therapies for NSCLC and review new HER2-targeted therapies, international study results, and the promise of evolving targeted approaches for HER2-altered lung cancer.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/TBU865. CME/MOC/AAPA credit will be available until December 20, 2026.Next-Generation Solutions to Optimize Glioma Care: Applying The Latest Evidence on Molecularly Targeted Therapies in IDH-Mutant Disease In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and American Brain Tumor Association. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Servier Pharmaceuticals LLC.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/KFF865. CME/MOC/NCPD/AAPA/IPCE credit will be available until December 21, 2026.Turning the Tide in Gastric Cancer Management: Integrating Modern Systemic Therapies Across the Disease Continuum for Community-Based Clinicians In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca and Daiichi Sankyo, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/TBU865. CME/MOC/AAPA credit will be available until December 20, 2026.Next-Generation Solutions to Optimize Glioma Care: Applying The Latest Evidence on Molecularly Targeted Therapies in IDH-Mutant Disease In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and American Brain Tumor Association. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Servier Pharmaceuticals LLC.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/KFF865. CME/MOC/NCPD/AAPA/IPCE credit will be available until December 21, 2026.Turning the Tide in Gastric Cancer Management: Integrating Modern Systemic Therapies Across the Disease Continuum for Community-Based Clinicians In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca and Daiichi Sankyo, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/TBU865. CME/MOC/AAPA credit will be available until December 20, 2026.Next-Generation Solutions to Optimize Glioma Care: Applying The Latest Evidence on Molecularly Targeted Therapies in IDH-Mutant Disease In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and American Brain Tumor Association. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Servier Pharmaceuticals LLC.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/TBU865. CME/MOC/AAPA credit will be available until December 20, 2026.Next-Generation Solutions to Optimize Glioma Care: Applying The Latest Evidence on Molecularly Targeted Therapies in IDH-Mutant Disease In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and American Brain Tumor Association. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Servier Pharmaceuticals LLC.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/KFF865. CME/MOC/NCPD/AAPA/IPCE credit will be available until December 21, 2026.Turning the Tide in Gastric Cancer Management: Integrating Modern Systemic Therapies Across the Disease Continuum for Community-Based Clinicians In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca and Daiichi Sankyo, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/TBU865. CME/MOC/AAPA credit will be available until December 20, 2026.Next-Generation Solutions to Optimize Glioma Care: Applying The Latest Evidence on Molecularly Targeted Therapies in IDH-Mutant Disease In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and American Brain Tumor Association. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Servier Pharmaceuticals LLC.Disclosure information is available at the beginning of the video presentation.

Send us a textAs 2025 comes to a close, Ben and Daphna reflect on a year of growth, community, and evolution for The Incubator Podcast. In this end-of-year wrap-up, they preview major changes coming in 2026, including new standalone podcast feeds, expanded journal club content, CME opportunities, and exciting partnerships with organizations like the Vermont Oxford Network and PAS. They also share what's ahead for the Delphi Conference and offer a candid look at their personal and professional goals for the year ahead. Thank you for being part of this extraordinary neonatal community. Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!

Drs. Herzberg and Yu explore emerging clinical data from the 2025 meetings of the European Society For Medical Oncology (ESMO) and World Conference on Lung Cancer (WCLC), highlighting recent advancements in HER2-targeted therapies for NSCLC. Their discussion focuses on new drugs (eg, zongertinib and trastuzumab deruxtecan), their efficacy and safety profiles, and the potential for treating HER2 mutations and overexpression.

Send us a textTransitioning from fellowship to your first attending job? You're probably not prepared for the business side of medicine—and that's exactly the problem Dr. Tung Giep addresses in this episode. Dr. Giep, a neonatologist with over 30 years of experience, shares hard-earned lessons from building and selling a private practice in Houston, navigating toxic work environments, and eventually finding his place in telemedicine. His new book, The Business of Medicine: The Definitive Guide to Help New Physicians Start Their Career on the Right Path and Avoid Costly Mistakes, tackles what medical training ignores: contract negotiation, non-competes, choosing the right CPA and attorney, and understanding your self-worth.Ben and Dr. Giep discuss why new physicians get blindsided by job offers, how to vet a practice properly, and the reality of community neonatology versus academic medicine. They also explore the growing role of AI in healthcare and what it means for the next generation of physicians. Whether you're finishing fellowship or reconsidering your current position, this conversation offers practical guidance on taking control of your career—and avoiding costly mistakes along the way. Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!

Join us in this episode with expert guest Dr. Mahvish Rahim (the Children's Hospital at Montefiore) as we dive into the rapidly evolving world of curative and transformative therapies for sickle cell disease! From breaking down the science behind stem cell transplant and gene therapy to understanding how to choose the right candidates and counsel families, Dr. Rahim brings clarity to this exciting new era in SCD care.

Our series concludes with Cathy Carson sharing about energy medicine, and specifically, things that you could do for self or others.

In this episode of Off Script, we continue our conversation with Jason Bock, co-founder and CEO of CTMC, diving deeper into the operational and manufacturing challenges shaping the future of curative cell therapies. Jason discusses how CTMC—through its partnership with MD Anderson Cancer Center—is eliminating inefficiencies across development timelines to significantly accelerate clinical progress without increasing risk. He also shares a forward-looking perspective on how cell therapies could one day be ordered and delivered like traditional pharmaceuticals, and what scientific, regulatory, and manufacturing innovations will be required to make that vision a reality.

In this episode of the Oncology Brothers podcast, we are joined by Dr. Komal Jhaveri, a breast medical oncologist at Memorial Sloan Kettering, to discuss the evolving landscape of metastatic hormone receptor positive breast cancer, particularly focusing on low and ultra-low HER2 expression. Key topics include: • The significance of the DESTINY Breast-04 and DESTINY Breast-06 studies and their impact on treatment options. • The definition and implications of low and ultra-low HER2 expression in clinical practice. • The importance of HER2 testing and the dynamic nature of HER2 expression in tumors. • Treatment sequencing strategies, including the use of antibody-drug conjugates (ADCs) like trastuzumab deruxtecan (TDXd) and sasituzumab govitecan. • Management of treatment-related toxicities, including ILD, nausea, and alopecia. Join us for an insightful discussion that aims to keep healthcare professionals updated on the latest advancements in cancer care. Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Don't forget to subscribe for more episodes and insights!

Obesity affects more than 1 billion people worldwide and is recognized by the World Health Organization as a chronic, relapsing disease. WHO recently published a guideline in JAMA on the use and indications of GLP-1 therapies for the treatment of #obesity in adults. Francesca Celletti, MD, PhD, and Ezekiel Emanuel, MD, PhD, join JAMA Editor in Chief Kirsten Bibbins-Domingo, PhD, MD, MAS, to discuss. Related Content: World Health Organization Guideline on the Use and Indications of Glucagon-Like Peptide-1 Therapies for the Treatment of Obesity in Adults

This episode is sponsored by Zomedica. Live from dvm360's Fetch Kansas City conference, host Adam Christman, DVM, MBA, sits down with Nicole Westfall, MBA, senior vice president of marketing at Zomedica. In this episode, they explore the benefits of PulseVet Shock Wave Therapy and The Assisi Loop, highlighting how these innovative tools provide noninvasive, effective pain management for patients suffering from chronic conditions.

Master cardiovascular disease prevention! Learn how to apply the new PREVENT risk calculator, use the CPR framework for risk reclassification, and interpret ApoB and Lp(a) in modern lipid management. We're joined by Dr. Laurence Sperling to break down what's new in ASCVD risk assessment and prevention. Claim CME for this episode at curbsiders.vcuhealth.org! Patreon | Episodes | Subscribe | Spotify | YouTube | Newsletter | Contact | Swag! | CME Show Segments Intro Case 1 from Kashlak  Risk assessment framework ApoB and Non-HDL cholesterol Lipoprotein(a) and its importance The PREVENT risk score and its implications Statins and other lipid lowering therapies The role of diet and lifestyle in lipid management Case 2 from Kashlak Familial Hypercholesterolemia diagnosis and management Key takeaways Outro Credits Producer, Writer, Shownotes, Infographic, and Cover art: Ben Furman, MPH  Hosts: Matthew Watto MD, FACP; Paul Williams MD, FACP    Reviewer: Leah Witt, MD Showrunners: Matthew Watto MD, FACP; Paul Williams MD, FACP Technical Production: PodPaste Guest: Laurence Sperling, MD  Disclosures Dr. Sperling reports no relevant financial disclosures. The Curbsiders report no relevant financial disclosures. Sponsor: Bucksbaum-Siegler Institute If you want to learn more about what the Bucksbaum-Siegler Institute is doing and to nominate someone for the Clinical Excellence Award—you can check them out today. Visit bucksbauminstitute.uchicago.edu. Sponsor: Grammarly  Sign up for FREE and experience how Grammarly can elevate your professional writing from start to finish. Visit Grammarly.com/podcast.  Sponsor: Continuing Education Company Use promo code Curb30 to get 30% off all online courses and webcast. Visit CMEmeeting.org/curbsiders to learn more. Sponsor: Freed Use code: CURB50 to get $50 off your first month when you subscribe!

Send us a textHow ketosis and ketogenic diets work and how these tools can improve metabolic health, brain function, and even cancer management.Topics Discussed:Organs have different fuel preferences: brain strongly prefers glucose, heart prefers fatty acids, skeletal muscle is flexible and likes fat/ketones.Humans evolved with high metabolic flexibility; regular ketosis was normal for ancestors, but today most people never experience it.“Keto flu” is largely glucose withdrawal plus electrolyte/sodium loss; proper salt and hydration prevent most symptoms.Classic medical ketogenic diet is ~90% fat (historically saturated); modern versions often use more monounsaturated fats, MCTs, and higher protein.Saturated fat is not inherently atherogenic in the context of weight stability or caloric deficit; excess calories from any source can dysregulate metabolism.Exogenous ketones (e.g. BHB) provide energy, reduce ROS, stabilize membranes, increase inhibitory tone (GABA), and have hormone-like signaling effects independent of diet.Cancer cells often show Warburg effect (damaged mitochondrial respiration → heavy reliance on glycolysis); lowering glucose and raising ketones can stress cancer cells.True keto-adaptation for athletic performance requires 6–12 weeks; after that, elite athletes can match or exceed prior high-carb performance at sub-maximal and endurance efforts.Practical Takeaways:Therapeutic carbohydrate restriction (50–100 g/day for many people) plus occasional fasting or ketone supplements can restore metabolic flexibility with far fewer side effects than strict keto.Prioritize whole-food fats (eggs, fatty fish, beef, olive oil, butter/lard) and minimize processed keto products loaded with seed oils.Supplementing BHB (salts or esters) or MCT oil can ease the transition into ketosis, boost ketones without strict dieting, and may support brain and metabolic health.Regularly check basic blood markers (glucose, lipids, electrolytes) and consider an OmegaQuant test; optimizing metabolic health is one of the strongest preventable steps against cancer, neurodegeneration, and heart disease.Supplemental Ketone (BHB):KetoCitra—Ketone body BHB with potassium, calcium & magnesium, formulated with kidney health in mind. Use code MIND20 for 20% off.*Not medical advice.Support the showAffiliates: Lumen device to optimize your metabolism for weight loss or athletic performance. MINDMATTER gets you 15% off. AquaTru: Water filtration devices that remove microplastics, metals, bacteria, and more from your drinking water. Through link, $100 off AquaTru Carafe, Classic & Under Sink Units; $300 off Freestanding models. Seed Oil Scout: Find restaurants with seed oil-free options, scan food products to see what they're hiding, with this easy-to-use mobile app. KetoCitra—Ketone body BHB + electrolytes formulated for kidney health. Use code MIND20 for 20% off any subscription (cancel anytime) For all the ways you can support my efforts

View the Show Notes Page for This Episode Become a Member to Receive Exclusive Content Sign Up to Receive Peter's Weekly Newsletter Dom D'Agostino is a neuroscientist and professor at the forefront of metabolic therapies, including ketogenic diets, exogenous ketones, and hyperbaric oxygen. In this episode, Dom breaks down nutritional versus supplemental ketosis, defines meaningful ketone thresholds, and outlines practical ways to achieve ketosis. He explains how a ketogenic diet can support metabolic health and weight loss, and advises on how to maintain adequate protein and avoid common mistakes. Dom surveys the growing landscape of exogenous ketones—from salts and esters to 1,3-butanediol—and effective pairings like caffeine, MCT oil, and alpha-GPC. He highlights the role of ketogenic therapy in cancer (particularly glioblastoma) and its promise for neurodegenerative diseases. The conversation also covers recommended hyperbaric oxygen protocols for brain injuries and cognitive function, situations where fasting or ketones offer cognitive and anti-inflammatory benefits, and touches on the carnivore diet as a ketogenic variant with potential relevance for autoimmune and metabolic conditions. We discuss: Dom and Peter's shared interest in ketosis, and Dom's scientific journey [2:30]; Dom's work for the Navy on oxygen toxicity [7:00]; Nutritional ketosis defined: physiology, biomarkers, and how fasting and diet generate therapeutic ketones [15:00]; The historical roots of ketogenic diets in epilepsy treatment, and evidence showing ketones reduce seizure activity and strengthen brain resilience [19:00]; Dom's personal experience on the ketogenic diet: tracking macros, getting enough protein, and monitoring ketone levels [24:15]; Using a ketogenic diet for weight loss: Dom's guidance on protein, fiber, calorie tracking, lipid monitoring, and more [31:00]; Protein on ketogenic diets: Dom's rationale for higher intake and muscle preservation [38:00]; Incorporating carbohydrates into keto: timing, high-fiber foods, and other considerations [41:30]; The carnivore diet: whether this diet induces ketosis, how it functions metabolically, and why it may help individuals with autoimmune conditions [44:15]; Early exogenous ketones: how 1,3-butanediol works, its liver toxicity risk, and why ketone esters replaced it [48:15]; The progression of exogenous ketones: why BHB monoesters and ketone salts emerged as better alternatives to 1,3-butanediol for ketone supplementation [59:30]; Ketone salts: easing the transition into ketosis, dosing, and how they compare to ketone esters [1:04:00]; The differences between D- and L-β-hydroxybutyrate, and how racemic mixtures may elevate ketones longer and offer unique biological effects [1:09:30]; How ketosis may boost NAD, and why NAD supplements have fallen short so far [1:16:30]; Emerging evidence for using a ketogenic diet to treat anorexia and other psychiatric disorders [1:20:30]; Potential cognitive and performance benefits of ketone supplementation, and why pushing ketones too high can be dangerous [1:23:45]; Applications for ketone esters, and why ketone salts or MCT-blended formulations may be safer and more practical for most people [1:29:15]; The role of a ketogenic diet in treating cancer [1:34:45]; The potential of a ketogenic diet for treating Alzheimer's disease [1:45:45]; Tools for cognitive enhancement: ketones, alpha-GPC, MCT, caffeine, strategic fasting, and more [1:53:45]; Hyperbaric oxygen therapy for concussion, TBI, PTSD, and cognitive function, including protocols and dosing approaches [1:55:30]; Peter's takeaways, recommended products, and additional resources to learn more [2:03:00]; and More. Connect With Peter on Twitter, Instagram, Facebook and YouTube